- Home
- BHAT vs MAIA Comparison
BHAT vs MAIA Comparison
Compare BHAT & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BHAT | MAIA |
|---|---|---|
| Founded | 2010 | 2018 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 59.1M | 49.3M |
| IPO Year | 2019 | 2022 |
Fundamental Metrics
Financial Performance| Metric | BHAT | MAIA |
|---|---|---|
| Price | $0.74 | $2.34 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 521.1K | ★ 1.2M |
| Earning Date | 05-12-2026 | 03-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $18,972,415.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.67 | $0.87 |
| 52 Week High | $14.10 | $3.19 |
Technical Indicators
Market Signals| Indicator | BHAT | MAIA |
|---|---|---|
| Relative Strength Index (RSI) | 29.11 | 60.87 |
| Support Level | $1.11 | $2.25 |
| Resistance Level | $1.02 | $3.19 |
| Average True Range (ATR) | 0.12 | 0.29 |
| MACD | -0.03 | 0.04 |
| Stochastic Oscillator | 19.89 | 51.76 |
Price Performance
Historical ComparisonAbout BHAT Blue Hat Interactive Entertainment Technology
Blue Hat Interactive Entertainment Technology is focused on commodity trading, including chemicals, jewelry, and precious metals such as gold. It operates a gold and diamond trading and supply chain business. Its business model encompasses physical gold trading, diamond trading, gold derivatives trading, and the development of AI-enabled trading platforms. Its segments include Diamond trading, Commodity trading, Information service, Interactive toys - animation series, and Interactive toys - game series. It derives revenue from Diamond trading. The majority of its revenues are generated in PRC.
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.